AIs are an evidence-based adjuvant endocrine therapy for postmenopausal women with early-stage breast cancer, including those with chemotherapy-induced ovarian function failure. However, therapy with AIs is not effective for women with functioning ovaries. To add to the information in the medical literature regarding the frequency of OFR during a switch to AIs after tamoxifen therapy in patients with early breast cancer, Vivianne C.G. TjanHeijnen, MD, PhD, head of the department of medical oncology at Maastricht University Medical Center in Maastricht, the Netherlands, performed a subanalysis of the DATA trial to address this question.

中文翻译：

---

化疗引起闭经的女性从辅助他莫昔芬治疗转为芳香酶抑制剂治疗时，应考虑卵巢功能恢复的风险

AIs 是一种基于证据的辅助内分泌治疗，适用于患有早期乳腺癌的绝经后妇女，包​​括化疗引起的卵巢功能衰竭的妇女。然而，AIs 治疗对卵巢功能正常的女性无效。为了补充医学文献中关于早期乳腺癌患者在他莫昔芬治疗后改用 AIs 期间 OFR 频率的信息，Vivianne CG TjanHeijnen，医学博士，博士，马斯特里赫特大学医学中心医学肿瘤学系主任荷兰马斯特里赫特对 DATA 试验进行了子分析以解决这个问题。